Literatur
- 1
The Heart Outcomes Prevention Evaluation Study Investigators .
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular
events in high-risk patients.
N Engl J Med.
2000;
342
145-153
- 2
Dahlöf B, Devereux R B, Kjeldsen S E. et al .
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction
in hypertension study (LIFE): a randomised trial against atenolol.
Lancet.
2002;
359
995-1003
- 3 Dahlöf B, Severs P, Poulter N R. et al .Prevention of cardiovascular events with
an antihypertensive regimen of amlodipine adding perindopril as required versus atendol
adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes
Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled
trial. Lancet Published online September 4, 2005 2005
- 4
Sleight P, Yusuf S, Pogue J. et al .
Blood-pressure reduction and cardiovascular risk in the HOPE-study.
Lancet.
2001;
358
2130-2131
- 5
Bosch J, Yusuf S, Pogue J. et al .
Use of ramipril in preventing stroke: double blind randomised trial.
BMJ.
2002;
324
699-702
- 6
Svensson P, de Faire U, Sleight P. et al .
Comparative effects of ramipril on ambulatory and office blood pressure: a HOPE Substudy.
Hypertension.
2001;
38
E28-E32
- 7
The ALLHAT officers and coordinators for the ALLHAT collaborative Research Group .
Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting
enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and
Lipid-Lowering treatment to Prevent Heart Attack Trial (ALLHAT).
JAMA.
2002;
288
2981-2997
- 8
Julius S, Kjeldsen S E, Weber M. et al .
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens
based on valsartan or amlodipine: The VALUE randomised trial.
Lancet.
2004;
363
2022-2031
- 9
The EURopean trial on reduction of cardiac events with Perindopril in stable corornary
Artery disease Investigators .
Efficacy of perindopril in reduction of cardiovascular events among patients with
stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre
trial (the EUROPA study).
Lancet.
2003;
362
782-788
- 10
The PEACE Trial Investigators .
Angiotensin-Converting-Enzyme Inhibition in stable coronary artery disease.
N Engl J Med.
2004;
351
2058-2068
- 11
Yusuf S, Pogue J.
ACE inhibition in stable coronary artery disease.
N Engl J Med.
2005;
352
937-938
- 12
Rangoonwala B.
Erfahrungen mit der Realisierung innovativer Studiendesigns am Beispiel der HOPE-Studie.
Dtsch Med Wochenschr.
2005;
130
S82-S85
Dr. PhD. B. Rangoonwala
Dahlienweg 11
65719 Hofheim/Ts
